Search results for "26"

showing 10 items of 3194 documents

Size and subclasses of low-density lipoproteins in patients with obstructive sleep apnea.

2012

Patients with obstructive sleep apnea (OSA) have proatherogenic dyslipidemia. We analyzed predictors of low-density lipoproteins' (LDLs) size in patients with OSA. In a cross-sectional study including 58 participants with OSA (30 without the metabolic syndrome [MetS] and 28 with MetS), we evaluated the size of LDL by gradient gel electrophoresis. Compared with patients without the MetS, those with MetS showed lower LDL size ( P = .007), due to a reduction in large LDL-I particles ( P = .002) and an increase in small, dense LDL-IIIA ( P = .048) and LDL-IIIB ( P = .037). The size of LDL correlated inversely with age ( r = −.268, P = .042) and serum triglycerides ( r = −.364, P = .005), and p…

medicine.medical_specialtyCross-sectional studyPolysomnography10265 Clinic for Endocrinology and Diabetology610 Medicine & healthPolysomnography2705 Cardiology and Cardiovascular MedicineInternal medicinemedicineLow densityobstructive sleep apnea metabolic syndrome low-density lipoprotein size small dense low-density lipoprotein atherosclerosisHumansIn patientDyslipidemiasMetabolic SyndromeSleep Apnea Obstructivemedicine.diagnostic_testbusiness.industrySleep apneamedicine.diseaseLipoproteins LDLObstructive sleep apneaCross-Sectional StudiesEndocrinologyLinear Modelslipids (amino acids peptides and proteins)Metabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemia
researchProduct

Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum

2019

Introduction: Pyoderma gangrenosum (PG) is a noninfectious, reactive inflammatory neutrophilic dermatosis that is commonly associated with autoimmune and neoplastic disorders. There are emerging diagnostic tools and treatment options for PG.Area covered: The diagnosis of PG should be seriously considered when managing ulcers to avoid unnecessary medical and surgical complications with prompt and suitable treatment. There are no standardized treatment guidelines for PG, and current therapy largely depends on the severity and progression of the disease. Systemic corticosteroids, immunosuppressant therapy, and biologic agents remain mainstay therapies. In this article, we present a literature …

medicine.medical_specialtyDiseaseDiagnostic toolsSeverity of Illness Index030226 pharmacology & pharmacySystemic therapyBiological Factors03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesmedicineHumansPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsIntensive care medicineClinical treatmentbusiness.industryGeneral MedicineGold standard (test)medicine.diseasePyoderma GangrenosumBiologic AgentsNeutrophilic dermatosis030220 oncology & carcinogenesisDisease ProgressionDermatologic AgentsbusinessImmunosuppressive AgentsPyoderma gangrenosumExpert Review of Clinical Pharmacology
researchProduct

Prolonged-release buprenorphine formulations: Perspectives for clinical practice

2020

International audience; Buprenorphine and methadone are the two main opioid agonist treatments approved for opioid use disorder. Buprenorphine is a partial agonist of the mu opioid receptors, which has been merely available through sublingual form until now. In practice, the use of buprenorphine is smoother than that of methadone, and it induces reduced risks of overdose. However, sublingual buprenorphine also exposes to risks (e.g., withdrawal, misuse) and constraints (e.g., daily intake). Three new galenic formulations of prolonged-release buprenorphine (PRB) are being commercialized and should allow some improvements in patients' comfort and safety. This narrative review aims to describe…

medicine.medical_specialtyDoseNarcotic Antagonists[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthReceptors Opioid mu030226 pharmacology & pharmacyPartial agonistOpioid dependenceDependance aux opioides03 medical and health sciencesSubcutaneous injection0302 clinical medicineProlonged releasemedicineHumansProlonged-releasePharmacology (medical)OpiacésAction prolongeebusiness.industryOpioid use disorderOpioid-Related Disordersmedicine.disease3. Good healthBuprenorphineAnalgesics OpioidOpiatesOpioid[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthEmergency medicinebusinessSubstitutionMethadoneBuprenorphinemedicine.drugMethadone
researchProduct

Unpredictable Performance of pH-Dependent Coatings Accentuates the Need for Improved Predictive in Vitro Test Systems.

2017

First introduced in the second half of the 19th century, enteric coatings are commonly used to protect acid-labile drugs, reduce the risk of gastric side effects due to irritating drugs, or for local drug delivery to the lower gastrointestinal (GI) tract. The currently available enteric-coatings are based on pH-sensitive weakly acidic polymers. Despite the long history of their use, the causes behind their performance often being unpredictable have not been properly investigated with most of the attention being focused only on the gastric emptying. However, little attention has been given to the postgastric emptying disintegration and dissolution of these dosage forms. This lack of attentio…

medicine.medical_specialtyDrug LiberationIn vitro testChemistry PharmaceuticalPharmaceutical SciencePh dependentBiological Availability02 engineering and technologyPharmacologyIn Vitro Techniques030226 pharmacology & pharmacyDosage formBiopharmaceuticsExcipients03 medical and health sciences0302 clinical medicineDrug DiscoveryIntestine SmallmedicineIntensive care medicineGastric emptyingbusiness.industryHydrogen-Ion Concentration021001 nanoscience & nanotechnologyEnteric coatingBioavailabilityDrug LiberationSolubilityDrug deliveryMolecular MedicineTablets Enteric-Coated0210 nano-technologybusinessmedicine.drugMolecular pharmaceutics
researchProduct

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance

2021

Introduction Immune checkpoint inhibitors (ICIs) are widely used in the treatment of many cancers as they improve clinical outcomes. However, ICIs have also been associated with the development of immune-related adverse drug reactions (ADRs). Among immune-related ADRs, cardiac immune-related ADRs are rare, but also associated with high mortality rates. Objective The objective of this study was to evaluate the occurrence of cardiac ADRs reported with ICIs in the European spontaneous reporting system. Methods We retrieved individual case safety reports on ICI-induced cardiac ADRs from the website of suspected ADR (www.adrreports.eu) of the European pharmacovigilance database (Eudravigilance).…

medicine.medical_specialtyDurvalumabDrug-Related Side Effects and Adverse ReactionsIpilimumabPembrolizumabToxicology030226 pharmacology & pharmacyPharmacovigilance03 medical and health sciences0302 clinical medicineAtezolizumabInternal medicinePharmacovigilancemedicineHumansPharmacology (medical)Original Research Article030212 general & internal medicineMyocardial infarctionImmune Checkpoint InhibitorsPharmacologybusiness.industryOdds ratiomedicine.diseaseIpilimumabNivolumabNivolumabbusinessmedicine.drugDrug Safety
researchProduct

Development of a fuzzy expert system for the control of glycemia in type 1 diabetic patients

2011

Abstract The paper describes the structure and the characteristics of an expert system that allows the optimization of postprandial glycemia in type 1 diabetic patients. The expert system is able to provide patients with the number of rapid insulin units that must be taken in order to keep the blood glucose level close to the omeostatic condition in the hours following a meal.

medicine.medical_specialtyFuzzy logic systemSettore ING-IND/26 - Teoria Dello Sviluppo Dei Processi ChimiciFuzzy expert systembusiness.industryInsulinmedicine.medical_treatmentControl (management)computer.software_genremedicine.diseaseExpert systemEndocrinologyPostprandialInternal medicineDiabetes mellitusEmergency medicinemedicinebusinesscomputerfuzzy logic system neuro fuzzy system expert system diabetes mellitus glycemia control
researchProduct

Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans.

2020

Abstract Objectives The inter-individual variability of warfarin dosing has been linked to genetic polymorphisms. This study was aimed at performing genotype-driven pharmacokinetic (PK) simulations to predict warfarin levels in Puerto Ricans. Methods Analysis of each individual dataset was performed by one-compartmental modeling using WinNonlin®v6.4. The k e of warfarin given a cytochrome P450 2C9 (CYP2C9) genotype ranged from 0.0189 to 0.0075 h−1. K a and V d parameters were taken from literature. Data from 128 subjects were divided into two groups (i.e., wild-types and carriers) and statistical analyses of PK parameters were performed by unpaired t-tests. Results In the carrier group (n=6…

medicine.medical_specialtyGenotypeCmax030204 cardiovascular system & hematology030226 pharmacology & pharmacyGastroenterologyArticle03 medical and health sciences0302 clinical medicinePharmacokineticsVitamin K Epoxide ReductasesInternal medicineGenotypemedicineHumansPharmacology (medical)DosingGeneral Pharmacology Toxicology and PharmaceuticsCYP2C9GenotypingCytochrome P-450 CYP2C9business.industryWarfarinArea under the curveFarmàcia InvestigacióAnticoagulantsHispanic or LatinoAryl Hydrocarbon HydroxylasesWarfarinbusinessmedicine.drugDrug metabolism and personalized therapy
researchProduct

Genetic counselling in ALS: facts, uncertainties and clinical suggestions

2013

The clinical approach to patients with amyotrophic lateral sclerosis (ALS) has been largely modified by the identification of novel genes, the detection of gene mutations in apparently sporadic patients, and the discovery of the strict genetic and clinical relation between ALS and frontotemporal dementia (FTD). As a consequence, clinicians are increasingly facing the dilemma on how to handle genetic counselling and testing both for ALS patients and their relatives. On the basis of existing literature on genetics of ALS and of other late-onset life-threatening disorders, we propose clinical suggestions to enable neurologists to provide optimal clinical and genetic counselling to patients and…

medicine.medical_specialtyGenotypeGENETICSGenetic counselingGenetic CounselingGene mutationSettore MED/03 - GENETICA MEDICAmedicineHumansGenetic TestingAmyotrophic lateral sclerosisGenetic discriminationPsychiatryGenetic testingmedicine.diagnostic_testbusiness.industryAmyotrophic Lateral Sclerosismedicine.diseasePenetranceALS; GENETICS3. Good healthPsychiatry and Mental healthPhenotypeFrontotemporal DementiaMutationSurgerySettore MED/26 - NeurologiaNeurology (clinical)ALSbusinessMotor neurone diseaseFrontotemporal dementiaJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome

2019

What is known and objective Mebendazole (MBZ) is a broad-spectrum antihelminthic agent of the benzimidazole type. Although MBZ has been reported to cause hepatic injury, case reports of severe hepatic injury are very rare. We report a case of severe hepatitis after administration of MBZ in a patient with Gilbert's syndrome affected by pinworms infestation. Case summary Differently from other cases of hepatitis due to MBZ reported in the scientific literature, our patient received standard doses of MBZ for a short period of time. After 18 days from the start of therapy, he developed hepatomegaly, and increases in hepatic enzymes and bilirubin. Hepatic enzymes returned to normal over the foll…

medicine.medical_specialtyGlucuronosyltransferaseSettore MED/17 - Malattie InfettiveBilirubinMebendazoleGlucuronidation030226 pharmacology & pharmacyGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMedicinePharmacology (medical)030212 general & internal medicinePharmacologyHepatitisLiver injurybiologybusiness.industrydrug toxicity Gilbert's syndrome hepatitis mebendazolemedicine.diseaseAntihelminthic AgentGilbert's syndromechemistrySettore BIO/14 - Farmacologiabiology.proteinbusinessmedicine.drugJournal of Clinical Pharmacy and Therapeutics
researchProduct

Cardiovascular comorbidity in multiple sclerosis patients treated with mitoxantrone therapy: a cohort study

2017

Abstract Background Mitoxantrone (MX) has been used as second line therapy for aggressive multiple sclerosis (MS). Potential cardiotoxic effects of MX limit its use; a cumulative dose of up to 100 mg/m2, has been long considered relatively safe. We calculated the frequency of cardiac side effects in MS patients treated with MX. Methods We performed a cohort study including all MS patients treated with MX at the Neurological Department of the University Hospital of Palermo, Italy. Two hundred-sixty-four MS patients diagnosed according to validated criteria were included and followed-up until the end of September 2010. Patients were treated with MX as a second line therapy if they had no prev…

medicine.medical_specialtyImmunologyHeart failureComorbidity030204 cardiovascular system & hematologylcsh:RC346-429Multiple sclerosis03 medical and health sciences0302 clinical medicineInternal medicinemedicineImmunology and AllergyMyocardial infarctionlcsh:Neurology. Diseases of the nervous systemMitoxantroneEjection fractionmedicine.diagnostic_testCumulative dosebusiness.industryComorbidity Multiple sclerosis Heart failure Mitoxantrone Therapymedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareNeurologyHeart failureCohortPhysical therapySettore MED/26 - NeurologiaTherapyNeurology (clinical)MitoxantronebusinessElectrocardiography030217 neurology & neurosurgeryCohort studymedicine.drug
researchProduct